TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M

TG THERAPEUTICS, INC.

Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.
Preliminary Q4 2023 BRIUMVI U.S. net product revenue ~$40M, full year ~$89M; year-end cash ~$215M.
2024 guidance: BRIUMVI U.S. net product revenue target $220-260M, Q1 target $41-46M; operating expense ~$250M.
2024 pipeline milestones: start trials for subcutaneous BRIUMVI, BRIUMVI in other autoimmune diseases, and azer-cel in autoimmune disease.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TG THERAPEUTICS, INC. entered into License Agreement with Precision BioSciences, Inc. valued at $7.5 million (effective 2024-01-07).

Action: entry
Agreement: license
Counterparty: Precision BioSciences, Inc.
Value: $7.5 million
Effective: 2024-01-07

Exact text from the filing

On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-001061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.